Bariatric Surgery Combined With GLP-1 Receptor Agonists Study
Recruiting · NCT07336862 · Interventional (participants receive a specific treatment)
View the official record on ClinicalTrials.gov →Interventions studied
BS groupBS-GLP group
What this trial is about
Obese patients exhibit considerable heterogeneity and complex comorbidities, making long-term effective management challenging with single therapies. While bariatric surgery remains the most effective weight-loss intervention, postoperative weight regain and metabolic deterioration require attention. GLP-1 RAs offer distinct advantages for weight and metabolic improvement, and their combined application with surgery may yield synergistic benefits. This study investigates the efficacy and safety of bariatric surgery combined with GLP-1 receptor agonist adjuvant therapy for severe obesity.
Who can take part
Age range
18 Years to 60 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Primary metabolic surgery candidates: Patients undergoing initial laparoscopic sleeve gastrectomy (LSG)
- obesity:BMI ≥35 kg/m²
- Metabolic comorbidities: Diagnosis of metabolic syndrome or type 2 diabetes mellitus (T2DM) meeting standard criteria
- Age range: 18-60 years (inclusive)
- Informed consent: Willing participation with documented consent
Exclusion criteria
- Recent GLP-1RA use: Treatment with GLP-1 receptor agonists within 6 months preoperatively
- Prior bariatric surgery: History of any metabolic/bariatric surgical procedure
- Postoperative complications: Requiring reoperation for severe complications (e.g., hemorrhage, anastomotic leak)
- Non-indicated candidates: Patients not meeting standard bariatric surgery indications
- Significant comorbidities:
- Advanced hepatic/renal dysfunction (Child-Pugh C or eGFR \<30 mL/min/1.73m²)
- Active malignancy (except non-melanoma skin cancers)
- Autoimmune disorders requiring immunosuppression
- Uncontrolled psychiatric conditions (e.g., active psychosis, severe depression)
Where it is running
1 location listed.
- China-Japan Friendship Hospital - Beijing, China